Updated

Recent research suggests that GLP-1 medications such as Ozempic may increase the risk of a rare eye disease that can cause partial or complete vision loss, prompting awareness among users and clinicians. Diagnostic testing is emerging as a tool for patients using the drugs to better understand their individual risk profile and monitor for early warning signs of visual complications. The finding represents an emerging safety consideration for the class of diabetes and weight-loss drugs that have driven significant demand and revenue growth for pharmaceutical companies in recent years, particularly as usage has expanded beyond the diabetic population into broader obesity treatment markets.